A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2019
At a glance
- Drugs ABX 1431 (Primary)
- Indications Central pain; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Abide Therapeutics
- 23 Jan 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2018 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.